March 2023 – Neurolixis Announces Positive Ph2A Proof-of Concept on NLX-112 in Levodopa-Induced Dyskinesia in Parkinson’s Disease

A Phase IIA clinical trial for treating LID using a novel small molecule performed in collaboration with our clinical team has yielded positive results. Click below to download the full press release.